Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1964 2
1965 2
1967 2
1968 2
1974 1
1975 2
1976 8
1977 10
1978 6
1979 3
1980 6
1981 12
1982 13
1983 12
1984 10
1985 17
1986 13
1987 22
1988 12
1989 15
1990 18
1991 25
1992 12
1993 21
1994 18
1995 21
1996 17
1997 13
1998 19
1999 17
2000 29
2001 39
2002 40
2003 43
2004 46
2005 44
2006 45
2007 82
2008 62
2009 57
2010 46
2011 64
2012 63
2013 70
2014 70
2015 75
2016 54
2017 58
2018 95
2019 111
2020 131
2021 126
2022 103
2023 110
2024 108
2025 99

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,018 results

Results by year

Filters applied: . Clear all
Page 1
Measuring fatigue: a meta-review.
Machado MO, Kang NC, Tai F, Sambhi RDS, Berk M, Carvalho AF, Chada LP, Merola JF, Piguet V, Alavi A. Machado MO, et al. Among authors: alavi a. Int J Dermatol. 2021 Sep;60(9):1053-1069. doi: 10.1111/ijd.15341. Epub 2020 Dec 10. Int J Dermatol. 2021. PMID: 33301180
Panniculitis: a narrative review.
Maniam GB, Limmer EE, Gibson LE, Tolkachjov SN, Alavi A. Maniam GB, et al. Among authors: alavi a. Arch Dermatol Res. 2025 Feb 8;317(1):373. doi: 10.1007/s00403-025-03816-9. Arch Dermatol Res. 2025. PMID: 39921712 Review.
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study.
Cutler C, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, Ramakrishnan A, DeFilipp Z, Salhotra A, Chai-Ho W, Mehta R, Wang T, Arora M, Pusic I, Saad A, Shah NN, Abhyankar S, Bachier C, Galvin J, Im A, Langston A, Liesveld J, Juckett M, Logan A, Schachter L, Alavi A, Howard D, Waksal HW, Ryan J, Eiznhamer D, Aggarwal SK, Ieyoub J, Schueller O, Green L, Yang Z, Krenz H, Jagasia M, Blazar BR, Pavletic S. Cutler C, et al. Among authors: alavi a. Blood. 2021 Dec 2;138(22):2278-2289. doi: 10.1182/blood.2021012021. Blood. 2021. PMID: 34265047 Free PMC article. Clinical Trial.
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, Paul C, Giamarellos Bourboulis EJ, Villani AP, Schwinn A, Ruëff F, Pillay Ramaya L, Reich A, Lobo I, Sinclair R, Passeron T, Martorell A, Mendes-Bastos P, Kokolakis G, Becherel PA, Wozniak MB, Martinez AL, Wei X, Uhlmann L, Passera A, Keefe D, Martin R, Field C, Chen L, Vandemeulebroecke M, Ravichandran S, Muscianisi E. Kimball AB, et al. Among authors: alavi a. Lancet. 2023 Mar 4;401(10378):747-761. doi: 10.1016/S0140-6736(23)00022-3. Epub 2023 Feb 3. Lancet. 2023. PMID: 36746171 Clinical Trial.
IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial.
Ackerman L, Acloque G, Bacchelli S, Schwartz H, Feinstein BJ, La Stella P, Alavi A, Gollerkeri A, Davis J, Campbell V, McDonald A, Agarwal S, Karnik R, Shi K, Mishkin A, Culbertson J, Klaus C, Enerson B, Massa V, Kuhn E, Sharma K, Keaney E, Barnes R, Chen D, Zheng X, Rong H, Sabesan V, Ho C, Mainolfi N, Slavin A, Gollob JA. Ackerman L, et al. Among authors: alavi a. Nat Med. 2023 Dec;29(12):3127-3136. doi: 10.1038/s41591-023-02635-7. Epub 2023 Nov 13. Nat Med. 2023. PMID: 37957373 Free PMC article. Clinical Trial.
Wound Bed Preparation 2021.
Sibbald RG, Elliott JA, Persaud-Jaimangal R, Goodman L, Armstrong DG, Harley C, Coelho S, Xi N, Evans R, Mayer DO, Zhao X, Heil J, Kotru B, Delmore B, LeBlanc K, Ayello EA, Smart H, Tariq G, Alavi A, Somayaji R. Sibbald RG, et al. Among authors: alavi a. Adv Skin Wound Care. 2021 Apr 1;34(4):183-195. doi: 10.1097/01.ASW.0000733724.87630.d6. Adv Skin Wound Care. 2021. PMID: 33739948 Free PMC article.
Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study.
Kirby JS, Okun MM, Alavi A, Bechara FG, Zouboulis CC, Brown K, Santos LL, Wang A, Bibeau KB, Kimball AB, Porter ML. Kirby JS, et al. Among authors: alavi a. J Am Acad Dermatol. 2024 Mar;90(3):521-529. doi: 10.1016/j.jaad.2023.10.034. Epub 2023 Oct 21. J Am Acad Dermatol. 2024. PMID: 37871805 Free article. Clinical Trial.
Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit.
Høilund-Carlsen PF, Alavi A, Barrio JR, Castellani RJ, Costa T, Herrup K, Kepp KP, Neve RL, Perry G, Revheim ME, Robakis NK, Sensi SL, Vissel B. Høilund-Carlsen PF, et al. Among authors: alavi a. Ageing Res Rev. 2024 Aug;99:102348. doi: 10.1016/j.arr.2024.102348. Epub 2024 Jun 1. Ageing Res Rev. 2024. PMID: 38830549 Review.
Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo.
Montes de Oca R, Alavi AS, Vitali N, Bhattacharya S, Blackwell C, Patel K, Seestaller-Wehr L, Kaczynski H, Shi H, Dobrzynski E, Obert L, Tsvetkov L, Cooper DC, Jackson H, Bojczuk P, Forveille S, Kepp O, Sauvat A, Kroemer G, Creighton-Gutteridge M, Yang J, Hopson C, Yanamandra N, Shelton C, Mayes P, Opalinska J, Barnette M, Srinivasan R, Smothers J, Hoos A. Montes de Oca R, et al. Among authors: alavi as. Mol Cancer Ther. 2021 Oct;20(10):1941-1955. doi: 10.1158/1535-7163.MCT-21-0035. Epub 2021 Jul 12. Mol Cancer Ther. 2021. PMID: 34253590 Free PMC article.
2,018 results